Germany’s Bundestag and Bundesrat passed a health-insurance cost-savings law on July 10, 2026 (the GKV-Beitragssatzstabilisierungsgesetz) that sharply cuts back coverage of medical cannabis under the country’s statutory health insurance system, known as the GKV, the public plan that covers roughly 90% of Germans. For the estimated 65,000 patients currently receiving cannabis flower or compounded cannabis prescriptions through their insurance, the practical effects are significant. By the way, we got the first patients with medical Cannabis in Germany in 2017 already!
What’s changing
- Dried cannabis flower is dropped from coverage entirely. No exceptions by diagnosis, insurers simply won’t pay for it anymore.
- Extracts, dronabinol, and nabilone remain technically reimbursable, but only after patients complete a mandatory six-month trial of an approved finished pharmaceutical product first. Currently there are just three such approved products on the German market: Sativex (for MS-related spasticity), Epidyolex (certain epilepsy syndromes), and Canemes (nausea from chemotherapy).
- Chronic pain patients are in a bind. Chronic pain is the single largest reason cannabis is prescribed in Germany, yet none of the three approved products is indicated for it. That means many patients would have to undergo a mandatory trial of a medicine that isn’t approved for their condition an “off-label” use before regaining access to the extract or flower that was already working for them.
- No transition protection. Patients who are currently stable on a long-standing flower or extract regimen get no grandfathering; the new rules apply across the board.
- Private-pay remains an option, but not a real fix. Anyone who can pay out of pocket can still get a private prescription for flower or extracts. For patients with ongoing needs and limited income, that’s not a sustainable substitute for insurance coverage.
How big is the actual disruption?
Berlin pharmacist Melanie Dolfen, who specializes in medical cannabis dispensing, has warned that a large share of the roughly 65,000 patients currently on a cannabis prescription would be left without coverage overnight. Compounded preparations — extracts, capsules, oils, suppositories, and topical creams , supply the overwhelming majority of these patients, she notes, while very few finished cannabis pharmaceuticals exist at all, and the handful that do are approved for only a narrow set of conditions. Dolfen also argues the governing coalition appears to hold underlying biases against flower-based therapy, personalized medicine, and pharmacy-led compounding -> biases she says ultimately only benefit the pharmaceutical industry.
The industry’s economic objection
The Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), the trade group representing cannabinoid manufacturers, argues the change won’t save any money and may do the opposite. BPC chair Antonia Menzel has said the rule forces physicians to prescribe products that can cost more per month than the compounded medicines patients already rely on, while typically not even being approved for most of the conditions being treated, calling the provision fundamentally out of place in a law meant to stabilize insurance contribution rates.
The German Hemp Association’s response
The Deutscher Hanfverband (DHV), Germany’s largest and longest-running cannabis advocacy group, called the vote a “scandalous decision” in its own press statement following the July 10 vote. The DHV’s core objection centers on one specific detail of how the law was pushed through: lawmakers repeatedly pointed to a newly approved cannabis-based finished medicine, Exilby, as the intended fallback option for patients losing flower and extract access, despite the fact that, at the time of the vote, no reimbursement price for that product had actually been negotiated with the GKV umbrella insurer body. Under German drug-pricing rules, a manufacturer can set its own price freely for the first six months after launch, with formal price negotiations only beginning after that. The DHV argues this makes it impossible to know in advance whether the law will actually deliver the savings it promises, since the cost of the product patients are being steered toward wasn’t yet fixed when the law was written.
The association also disputes the underlying premise of the reform on medical grounds: many patients currently doing well on individually selected cannabis flower strains or tailored compounded prescriptions may now have to work with their physician to determine whether switching to a reimbursable finished product is medically appropriate, a decision the DHV stresses rests solely with the treating physician, not the insurer. For patients who need fast symptom relief, particularly during acute pain flare-ups, the DHV and allied pharmacist groups warn that none of the newly prioritized finished pharmaceuticals offers a fast-acting inhaled option, leaving a real gap in care for that group.
Bottom line
The law takes effect immediately following passage, leaving patients and prescribing physicians to sort out next steps with little lead time. What unites the criticism from patient advocates (DHV), pharmacists (Dolfen and colleagues), and industry (BPC) is a shared doubt that the reform will actually cut costs paired with a shared warning that tens of thousands of patients now face real uncertainty about whether their existing, working treatment will still be covered.
Sources: Deutscher Hanfverband (hanfverband.de); Pharmazeutische Zeitung; krautinvest.de; Business of Cannabis.
